Platelet Function Test in Predicting the Efficacy and Safety of Clopidogrel Secondary Prevention of Ischemic Stroke#br#

doi:10.3969/j.issn.1673-5765.2021.06.008

Abstract

Abstract: Objective To evaluate the value of light transmittance aggregometry (LTA), thromboelastography (TEG) and platelet function analyzer (PFA) in predicting clinical outcome of the patients with minor ischemic stroke. Methods Acute minor ischemic stroke inpatients receiving clopidogrel for secondary prevention of ischemic stroke between May 2017 and February 2019 were consecutively collected. Residual platelet reactivity of five days after clopidogrel treatment was analyzed using LTA, TEG, and PFA. The main efficacy endpoint was recurrence of ischemic stroke, and the safety endpoint was antiplatelet therapy related bleeding. The platelet reactivity and CYP2C19 genotype were compared between recurrence group and non-recurrence group and between bleeding and non-bleeding group. Receiver operating characteristic curve analysis was used to evaluate the value of platelet function test in predicting ischemic stroke recurrence.

Results A total of 76 patients were included, and the median follow-up time was 13 months. 5

patients (6.58%) had recurrent ischemic stroke, and bleeding events occurred in 17 patients (22.37%). The on-treatment platelet reactivity by LTA [82.00% (76.00%-85.00%) vs 44.00% (27.00%-60.50%), P =0.005] and TEG [43.30% (34.40%-61.60%) vs 69.00% (52.45%-86.10%), P =0.032] analysis in patients with recurrent stroke was higher than that in patients without recurrent stroke. The area under the curve (AUC) was 0.88 (95%CI 0.73-1.00) for LTA and 0.79 (95%CI 0.61-0.97) for TEG. However, CYP2C19 genotype and PFA results were not associated with ischemic stroke recurrence. The platelet function results by the three tests were not associated with bleeding events. Conclusions LTA and TEG tests may predict 1-year recurrent ischemic stroke events in clopidogrel secondary prevention, while PFA test showed poor predictive power. None of the tests were effective in predicting antiplatelet related bleeding events.

Key words: Platelet function test; Ischemic stroke; Secondary prevention; Clopidogrel

摘要： 目的探讨透射光法血小板聚集实验（light transmittance aggregom etry，LTA）、血栓弹力图（thromboelastography，TEG）和血小板功能分析仪（platelet function analyzer，PFA）三种血小板功能实验对轻型缺血性卒中患者临床结局的预测价值。方法前瞻性连续收集2017年5月-2019年2月诊治为急性轻型缺血性卒中且长期服用氯吡格雷进行卒中二级预防的患者。分别采用LTA、TEG和PFA三种方法检测患者服用氯吡格雷5 d后的血小板反应性。2019年8月进行统一随访，主要终点事件为缺血性卒中复发，安全性结局为抗血小板药物相关的出血事件。比较缺血性卒中复发与未复发组、出血组与未出血组间LTA、TEG、PFA分别测定的血小板反应性差异及CYP2C19基因型分布的差异。采用受试者工作特征曲线分析血小板反应性对缺血性卒中复发的预测价值。结果研究共纳入76例患者，中位随访时间为13个月，其中5例（6.58%）患者缺血性卒中复发，17 例（22.37%）患者发生出血事件。LTA[82.00%（76.00%～85.00%）vs 44.00%（27.00%～60.50%）， P =0.005]和TEG[43.30%（34.40%～61.60%）vs 69.00%（52.45%～86.10%），P =0.032]检测的复发组血小板反应性显著高于未复发组；LTA和TEG检测结果对缺血性卒中复发有较好的预测价值[曲线下面积（area under the curve，AUC）分别为0.88（95%CI 0.73～1.00）和0.79（95%CI 0.61～0.97）]。 CYP2C19基因型和PFA检测结果均与缺血性卒中复发无关。三种血小板功能实验的结果与出血事件的发生率无关。结论当氯吡格雷用于缺血性卒中二级预防时，LTA和TEG实验对一年缺血性卒中复发有一定预测价值，但PFA预测能力欠佳。三种血小板功能实验结果与出血事件的发生无关。

关键词: 血小板功能实验; 缺血性卒中; 二级预防; 氯吡格雷

CHENG Yue, SHAO Teng-Fei, HUANG Li-Li, YANG Dan, XU Yun. Platelet Function Test in Predicting the Efficacy and Safety of Clopidogrel Secondary Prevention of Ischemic Stroke#br#[J]. Chinese Journal of Stroke, 2021, 16(06): 574-580.

程越, 邵腾飞, 黄丽丽, 杨丹, 徐运. 血小板功能实验预测氯吡格雷用于缺血性卒中二级预防的有效性和安全性分析[J]. 中国卒中杂志, 2021, 16(06): 574-580.

References

[1] LE QUELLEC S，BORDET J C，NEGRIER C，et
al. Comparison of current platelet functional tests for
the assessment of aspirin and clopidogrel response.
a review of the literature[J]. Thromb Haemost，2016，
116（4）：638-650.
[2] LIM S T，COUGHLAN C A，MURPHY S J，et al.
Platelet function testing in transient ischaemic attack
and ischaemic stroke：a comprehensive systematic
review of the literature[J]. Platelets，2015，26（5）：
402-412.
[3] FIOLAKI A，KATSANOS A H，KYRITSIS A P，et
al. High on treatment platelet reactivity to aspirin
and clopidogrel in ischemic stroke：a systematic
review and meta-analysis[J/OL]. J Neuro Sci，2017，
376：112-116[2020-10-27]. http：//doi.org/10.1016/
j.jns.2017.03.010.
[4] GROSS L，ARADI D，SIBBING D. Platelet function
testing in patients on antiplatelet medications[J].
Semin Thromb Hemost，2016，42（3）：306-320.
[5] RAO Z L，ZHENG H G，WANG F，et al. The
association between high on-treatment platelet
reactivity and early recurrence of ischemic events
after minor stroke or TIA[J]. Neurolo res，2017，39
（8）：719-726.
[6] ZHANG J B，ZHANG J S，SUN H R，et al.
Association between platelet function and recurrent
ischemic vascular events after TIA and minor
stroke[J]. Int J Clin Pharmacol Ther，2017，55（10）：
789-797.
[7] SHAO T F，CHENG Y，JIN J L，et al. A comparison
of three platelet function tests in ischemic stroke
patients with antiplatelet therapy[J/OL]. J Clin
Neurosci，2020，78：91-96[2020-10-27]. https：//doi.
org/10.1016/j.jocn.2020.06.004.
[8] 中华医学会神经病学分会，中华医学会神经病学分
会脑血管病学组. 中国急性缺血性脑卒中诊治指南
2014[J]. 中华神经科杂志，2015，48（10）：246-257.
[9] PATTI G，NUSCA A，MANGIACAPRA F，et
al. Point-of-care measurement of clopidogrel
responsiveness predicts clinical outcome in patients
undergoing percutaneous coronary intervention
results of the ARMYDA-PRO（Antiplatelet therapy
for Reduction of MYocardial Damage during
Angioplasty-Platelet Reactivity Predicts Outcome）
study[J]. J Am Coll Cardiol，2008，52（14）：1128-
1133.
[10] BOUMAN H J，HARMSZE A M，VAN WERKUM
J W，et al. Variability in on-treatment platelet
reactivity explained by CYP2C19 *2 genotype is
modest in clopidogrel pretreated patients undergoing
coronary stenting[J]. Heart，2011，97（15）：1239-
1244.
[11] FU H F，HU P，MA C M，et al. Association of
clopidogrel high on-treatment reactivity with clinical
outcomes and gene polymorphism in acute ischemic
stroke patients：an observational study[J/OL].

Medicine，2020，99（15）：e19472[2020-10-27].

https：//doi.org/10.1097/md.0000000000019472.
[12] YI X Y，LIN J，WANG Y F，et al. Association of
cytochrome P450 genetic variants with clopidogrel
resistance and outcomes in acute ischemic stroke[J].
J Atheroscler Thromb，2016，23（10）：1188-1200.
[13] GURBEL P A，GESHEFF M G，FRANZESE C
J，et al. Is light transmittance aggregometry still
a useful tool to assess pharmacodynamic effects
of antiplatelet therapy?[J]. Platelets，2015，26（6）：
608-609.
[14] RAO Z L，ZHENG H G，WANG F，et al. High
on-treatment platelet reactivity to adenosine
diphosphate predicts ischemic events of minor
stroke and transient ischemic attack[J]. J Stroke
Cerebrovasc Dis，2017，26（10）：2074-2081.
[15] ZHANG L M，LI X G，WANG D Z，et al. risk
factors of recurrent ischemic events after acute
noncardiogenic ischemic stroke[J]. Curr Pharm Des，
2019，25（45）：4827-4834.
[16] HAN Y，LV H H，LIU X，et al. Influence of genetic
polymorphisms on clopidogrel response and clinical
outcomes in patients with acute ischemic stroke
CYP2C19 genotype on clopidogrel response[J]. CNS
Neurosci Ther，2015，21（9）：692-697.
[17] FAVALORO E J，BONAR R. An update on quality
control for the PFA-100/PFA-200[J]. Platelets，2018，
29（6）：622-627.
[18] BREET N J，VAN WERKUM J W，BOUMAN H
J，et al. Comparison of platelet function tests in
predicting clinical outcome in patients undergoing
coronary stent implantation[J]. JAMA，2010，303
（8）：754-762.
[19] LIM H H，LI S，AN G D，et al. Platelet function
analyzer-200 P2Y results are predictive of the risk
of major adverse cardiac events in korean patients
receiving clopidogrel therapy following acute
coronary syndrome[J]. Ann Lab Med，2018，38（5）：
413-419.
[20] LATTUCA B，SILVAIN J，YAN Y，et al. Reasons
for the failure of platelet function testing to adjust
antiplatelet therapy：pharmacodynamic insights
from the ARCTIC study[J/OL]. Circ Cardiovasc
Interv，2019，12（11）：e007749[2020-10-27].
https：//doi.org/10.1161/circinterventions.118.007749.